Hacioglu, B. Et Al. 2015. How long should we maintain anti-HER2 therapy for metastatic breast cancer patients with complete remission?. FUTURE ONCOLOGY , vol.11, no.20 , 2799-2801.

Hacioglu, B., AKIN, S., BABACAN, T., SEVER, A. R., & Altundag, K., (2015). How long should we maintain anti-HER2 therapy for metastatic breast cancer patients with complete remission?. FUTURE ONCOLOGY , vol.11, no.20, 2799-2801.

Hacioglu, Bekir Et Al. "How long should we maintain anti-HER2 therapy for metastatic breast cancer patients with complete remission?," FUTURE ONCOLOGY , vol.11, no.20, 2799-2801, 2015

Hacioglu, Bekir Et Al. "How long should we maintain anti-HER2 therapy for metastatic breast cancer patients with complete remission?." FUTURE ONCOLOGY , vol.11, no.20, pp.2799-2801, 2015

Hacioglu, B. Et Al. (2015) . "How long should we maintain anti-HER2 therapy for metastatic breast cancer patients with complete remission?." FUTURE ONCOLOGY , vol.11, no.20, pp.2799-2801.

@article{article, author={Bekir Hacioglu Et Al. }, title={How long should we maintain anti-HER2 therapy for metastatic breast cancer patients with complete remission?}, journal={FUTURE ONCOLOGY}, year=2015, pages={2799-2801} }